Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
3.670
-0.070 (-1.87%)
At close: Nov 4, 2024, 4:00 PM
3.490
-0.180 (-4.90%)
After-hours: Nov 4, 2024, 5:08 PM EST
Leap Therapeutics Employees
Leap Therapeutics had 54 employees as of December 31, 2023. The number of employees increased by 10 or 22.73% compared to the previous year.
Employees
54
Change (1Y)
10
Growth (1Y)
22.73%
Revenue / Employee
n/a
Profits / Employee
-$1,117,463
Market Cap
140.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
MultiPlan | 2,800 |
InfuSystem Holdings | 516 |
Akoya Biosciences | 330 |
Seres Therapeutics | 233 |
Puma Biotechnology | 185 |
Generation Bio Co. | 174 |
Inovio Pharmaceuticals | 122 |
Fractyl Health | 102 |
LPTX News
- 5 weeks ago - Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - PRNewsWire
- 3 months ago - Leap Therapeutics Reports Second Quarter 2024 Financial Results - PRNewsWire
- 6 months ago - Leap Therapeutics Reports First Quarter 2024 Financial Results - PRNewsWire
- 7 months ago - Leap Therapeutics Announces $40 Million Private Placement - PRNewsWire
- 8 months ago - Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results - PRNewsWire
- 10 months ago - Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium - PRNewsWire
- 10 months ago - Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 10 months ago - Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients - PRNewsWire